XML 23 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Feb. 24, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Entity File Number 001-39539    
Entity Registrant Name PMV PHARMACEUTICALS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 46-3218129    
Entity Address, Address Line One 1 Research Way    
Entity Address, City or Town Princeton    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 08536    
City Area Code 609    
Local Phone Number 642-6670    
Title of 12(b) Security Common stock, par value $0.00001    
Trading Symbol PMVP    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company true    
Entity Common Stock, Shares Outstanding   45,773,361  
Entity Public Float     $ 543,361,107
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001699382    
Amendment Flag false    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Philadelphia, Pennsylvania    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive Proxy Statement relating to the 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2022.